KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Return on Capital Employed (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 15 years of Return on Capital Employed data on record, last reported at 0.09% in Q4 2025.

  • For Q4 2025, Return on Capital Employed rose 1.0% year-over-year to 0.09%; the TTM value through Dec 2025 reached 0.09%, up 1.0%, while the annual FY2025 figure was 0.1%, 0.0% changed from the prior year.
  • Return on Capital Employed reached 0.09% in Q4 2025 per ACAD's latest filing, up from 0.07% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.29% in Q3 2024 and bottomed at 0.41% in Q2 2021.
  • Average Return on Capital Employed over 5 years is 0.03%, with a median of 0.05% recorded in 2023.
  • Peak YoY movement for Return on Capital Employed: skyrocketed 36bps in 2021, then fell -22bps in 2025.
  • A 5-year view of Return on Capital Employed shows it stood at 0.06% in 2021, then crashed by -66bps to 0.1% in 2022, then soared by 74bps to 0.02% in 2023, then skyrocketed by 421bps to 0.08% in 2024, then increased by 14bps to 0.09% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Capital Employed were 0.09% in Q4 2025, 0.07% in Q3 2025, and 0.07% in Q2 2025.